Stock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price

Stock Track

Feb 06

Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.

The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.

Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180668695"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180668695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180668695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 02:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180668695","market":"us","top_or_hot":-1,"title":"Stock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price","media":"Stock Track","content":"<p>Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.</p><p>The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.</p><p>Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eikon Therapeutics Plummets 7.5% Intraday as Stock Debuts Below IPO Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-06 02:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.</p><p>The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.</p><p>Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EIKN","symbol_name":"Eikon Therapeutics","start_time":0,"source_url":"","article_id":"1180668695","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180668695","pubTimestamp":1770314678,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.The decline came as the stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EIKN":"Eikon Therapeutics"},"translate_title":"个股追踪|Eikon Therapeutics盘中暴跌7.5%股价低于IPO发行价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EIKN":1},"content_text":"Eikon Therapeutics (EIKN) shares plummeted 7.50% intraday on Thursday, marking a challenging start for the clinical-stage biopharmaceutical company's public market debut.The decline came as the stock began trading on the Nasdaq Global Select Market, opening at $17.05 per share, significantly below its initial public offering price of $18. The company had upsized its IPO to 21.8 million shares, pricing at the top of its expected $16-$18 range, but investor demand appeared weaker than anticipated at the opening bell.Founded in 2019 by Nobel laureates, Eikon Therapeutics is developing experimental cancer therapies, with its most advanced drug candidate EIK1001 undergoing mid-to-late stage clinical trials for skin cancer. Interim analysis data from this study is expected in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}